Evaluation of Interferon Treatment in Cirrhotic Patients with Hepatitis C

DOI Web Site PubMed 20 References
  • IDE Tatsuya
    The Second Department of Internal Medicine, Kurume University School of Medicine
  • SATA Michio
    The Second Department of Internal Medicine, Kurume University School of Medicine
  • SUZUKI Hiroshi
    The Second Department of Internal Medicine, Kurume University School of Medicine
  • MURASHIMA Shiroh
    The Second Department of Internal Medicine, Kurume University School of Medicine
  • MIYAJIMA Ichiroh
    The Second Department of Internal Medicine, Kurume University School of Medicine
  • SHIRACHI Miki
    The Second Department of Internal Medicine, Kurume University School of Medicine
  • TANIKAWA Kyuichi
    The Second Department of Internal Medicine, Kurume University School of Medicine

Bibliographic Information

Other Title
  • C型肝硬変患者におけるインターフェロンの治療効果
  • Evaluation of Interferon Treatment in C

Search this article

Abstract

The aim of this study was to examine the effects of interferon on cirrhotic patients with hepatitis C and the incidence of adverse reactions.<BR>The subjects were 35 cirrhotic patients, and 29 chronic active hepatitis patients without cirrhosis (CAH) served as controls. The cirrhotic patients received 3 or 6 million units of human lymphoblastoid interferon daily for one or two weeks and then three times a week for 22 or 23 weeks, while the CAH patients received 6 million units daily for 2 weeks and then three times a week for 14 or 16 weeks. Discontinuation of interferon treatment or dose reduction was required in the 7 cirrhotic patients. The most frequent reason was thrombocytopenia. Dose reduction alone was necessary in two CAH patients. Five cirrhotic patients (14.3%) and nine CAH patients (31.0%) were classified as complete responders to interferon treatment. In all five complete responders with cirrhosis, the hepatitis C virus RNA level before treatment was less than 5 log copies/50μl. The results of this study confirm the beneficial effect of interferon in selected patients with cirrhosis on basis of pre-treatment virus levels and platelet count.

Journal

  • Kansenshogaku Zasshi

    Kansenshogaku Zasshi 70 (6), 597-604, 1996

    The Japanese Association for Infectious Diseases

References(20)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top